Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke

The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and Sonke after a health department complaint alleging collusive practices in state medicine tenders. This early-stage probe echoes a prior inquiry into Hetero South Africa over a R15.5 billion AIDS drug tender awarded in August 2025, signaling intensified oversight of bidding processes. Details are scarce, with spokespersons from the commission, health department, and companies either declining comment or claiming unawareness.

Collusion Probes Hit State Medicine Bids

The Competition Commission has the power to investigate collusive tendering—like bid rotation, price fixing, and cover pricing—in state-supplied medicines. Targeted firms include Ascendis (recently delisted from the Johannesburg Stock Exchange), Pharma Q (partly owned by Indian firm Micro Labs), and Sonke (a Sun Pharma subsidiary), all supplying the South African state. This pharmaceutical tender investigation extends the commission’s action against Hetero South Africa, referred by the health department for alleged collusion in the massive AIDS drug tender, revealing a pattern targeting generic suppliers with Indian ties and escalating anti-competitive enforcement in public procurement.

Tender Collusion Threatens Drug Access and Costs

This pharmaceutical tender investigation exposes flaws in pricing and reimbursement for essential medicines like AIDS treatments in South Africa’s public sector. Collusion findings could bar suppliers, spike costs via invalidated tenders (as in past business rescues), and demand new reimbursement models. Amid industry pressures on generics, it pushes transparent bidding, value-based procurement, to protect taxpayer funds in strained systems.